ABOUT

INTUNIV is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents 6-17 years old, as monotherapy (when stimulants or atomoxetine are not suitable, not tolerated or have been shown to be ineffective) or as adjunctive therapy to psychostimulants (where there has been a sub-optimal response to psychostimulants).1 

INTUNIV must be used as part of a comprehensive ADHD management programme, typically including psychological, educational and social measures.1

Useful resources
icon
Title card
MECHANISM OF ACTION
icon
Title card
ADJUNCTIVE THERAPY CASE STUDY
icon
Title card
REQUEST INTUNIV SAMPLES
  1. Intuniv® (guanfacine hydrochloride) Approved Product Information.

PBS Information: This product is listed on the PBS. Authority required. Refer to PBS Schedule for full authority information.

Click here to review the full Product Information before prescribing.

You are now leaving the TakedaPro website

This link opens a website that is not operated by Takeda. We are not responsible for the content or availability of linked websites.

Cancel

Continue